WORLD HEALTH ORGANIZATION

The smart pills market was valued at USD 1.5 billion in 2023 and is projected to reach USD 4.9 billion by 2032, growing at a CAGR of 14.0%. Technological innovation and healthcare needs drive growth, with non-invasive methods gaining prominence. Regulatory approvals and clinical trials support market expansion, while smart pills offer potential healthcare cost savings of up to 20% globally by 2030.

The AI in precision medicine market is expected to grow from USD 0.78 billion in 2024 to USD 3.92 billion by 2030, driven by personalized treatments, advanced genomics, and drug development acceleration. AI analyzes complex data for quicker disease identification and tailored therapies, optimizing diagnostics and treatment outcomes. Key players include NVIDIA, Google, Microsoft, and IBM, focusing on innovations like deep learning and AI platforms for drug discovery.

EVA Pharma's insulin glargine injection, produced in collaboration with Eli Lilly, received approval from the Egyptian Drug Authority. This marks the first regulatory approval for EVA Pharma's insulin drug products, aiming to provide affordable insulin to one million people in low- to middle-income countries annually by 2030.

The RH5.1/Matrix-M malaria vaccine, studied in a Phase IIb trial, shows 55% efficacy against clinical malaria and over 80% against severe disease, with favorable safety and tolerability. It could complement existing pre-erythrocytic vaccines, offering a second line of defense against malaria.

Eli Lilly and EVA Pharma's collaboration led to the Egyptian Drug Authority approving EVA Pharma's insulin glargine injection, aiming to provide affordable insulin to one million people in low- to middle-income countries annually by 2030. This marks EVA Pharma's first regulatory approval, with ongoing efforts for WHO pre-qualification and expansion into treating immunological diseases.

Cholera causes 1.3-4 million cases and 21,000-143,000 deaths annually worldwide, with severe cases leading to rapid dehydration and death. WHO classifies its resurgence as a grade 3 emergency. Crofelemer, derived from the Croton lechleri tree, is FDA-approved for HIV/AIDS-related diarrhea. Jaguar Health focuses on plant-based medicines for gastrointestinal issues, including cholera treatment.

The bird flu outbreak among US dairy cows, first identified in Texas, has spread to 16 states, affecting 875 herds. Despite efforts, the government's response has been criticized as slow and inadequate, with fears of a potential pandemic. The virus has infected over 60 people, mainly through contact with cows or poultry, raising concerns about its evolution and spread. The situation highlights systemic issues in health security and the need for improved surveillance and protection for farmworkers.

The global AI in precision medicine market is expected to grow from USD 0.78 billion in 2024 to USD 3.92 billion by 2030, driven by the need for customized treatments, advancements in genomics, and the acceleration of drug development. AI's role in analyzing complex data enables quicker disease mechanism identification and tailored therapies. The market sees significant growth in neurology due to the challenges in diagnosing and treating neurological disorders. Key players like NVIDIA, Google, and Microsoft are advancing AI technologies for drug discovery and personalized healthcare, leveraging deep learning models and cloud platforms to enhance treatment predictions and patient outcomes.

The global personalized medicine biomarkers market is projected to grow from USD 21.85 billion in 2024 to USD 78.27 billion by 2034, at a CAGR of 13.6%. Biomarkers aid in early disease detection, prognosis, and treatment selection, driving market growth. Key drivers include advancements in genomics, growing prevalence of diseases like cancer, and partnerships between pharmaceutical and diagnostic firms. North America leads the market, while Asia Pacific is expected to grow fastest due to expanding healthcare infrastructure and rising demand for precision medicine.